Natera, Inc. (NASDAQ:NTRA) Shares Sold by First Hawaiian Bank

First Hawaiian Bank decreased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 26.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,209 shares of the medical research company's stock after selling 5,009 shares during the quarter. First Hawaiian Bank's holdings in Natera were worth $2,249,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of NTRA. Covestor Ltd boosted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after acquiring an additional 106 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Natera by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company's stock worth $441,000 after acquiring an additional 111 shares during the period. RiverPark Advisors LLC increased its stake in Natera by 3.5% in the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company's stock valued at $425,000 after purchasing an additional 112 shares in the last quarter. Finally, Fulton Bank N.A. raised its holdings in Natera by 3.8% during the fourth quarter. Fulton Bank N.A. now owns 3,581 shares of the medical research company's stock worth $567,000 after purchasing an additional 132 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Up 3.6 %

Shares of NTRA stock traded up $6.21 during trading hours on Thursday, hitting $176.61. 1,364,928 shares of the company were exchanged, compared to its average volume of 1,180,494. The stock has a market capitalization of $23.32 billion, a price-to-earnings ratio of -100.35 and a beta of 1.65. Natera, Inc. has a one year low of $59.80 and a one year high of $177.00. The business's 50-day simple moving average is $158.01 and its two-hundred day simple moving average is $131.36. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera's revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. Sell-side analysts predict that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NTRA. TD Cowen increased their price objective on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Piper Sandler raised their price target on Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research note on Monday, November 18th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. Morgan Stanley increased their target price on shares of Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Finally, The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $153.67.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now directly owns 111,891 shares of the company's stock, valued at approximately $13,434,752.37. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 1,767 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total value of $300,814.08. Following the completion of the sale, the director now directly owns 6,202 shares in the company, valued at approximately $1,055,828.48. This trade represents a 22.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,932 shares of company stock valued at $20,635,430 over the last 90 days. 7.60% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.